Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 5/20 | 0.70 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.70 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | MET | P08581 | 1/20 | 0.49 |
| ▸ | AURKA | O14965 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.48 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.48 |
| ▸ | MMP13 | P45452 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.47 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
| ▸ | PRKCG | P05129 | 1/20 | 0.47 |
| ▸ | PRKACA | P17612 | 1/20 | 0.47 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | AKT1 | P31749 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22319348 | 0.96 | PTGER4 (0.76) | PTGER4PTGER2MAPK14CYP3A4MMP13 | |
| SCHEMBL31028149 | 0.96 | PTGER4 (0.76) | PTGER4PTGER2MAPK14CYP3A4MMP13 | |
| SCHEMBL22319351 | 0.92 | PTGER4 (0.80) | PTGER4PTGER2EPHX2NR1H4LMNA | |
| SCHEMBL22319396 | 0.91 | PTGER4 (0.57) | PTGER4PTGER2MAPK14CYP3A4MET | |
| SCHEMBL31028174 | 0.91 | PTGER4 (0.85) | PTGER4PTGER2MAPK14CYP3A4EPHX2 | |
| SCHEMBL22319379 | 0.91 | PTGER4 (0.85) | PTGER4PTGER2MAPK14CYP3A4EPHX2 | |
| SCHEMBL31028172 | 0.90 | PTGER4 (0.80) | PTGER4PTGER2MAPK14CYP3A4EPHX2 | |
| SCHEMBL22319371 | 0.90 | PTGER4 (0.80) | PTGER4PTGER2MAPK14CYP3A4EPHX2 | |
| SCHEMBL22319380 | 0.89 | PTGER4 (0.70) | PTGER4PTGER2MAPK14CYP3A4 | |
| SCHEMBL31028146 | 0.89 | PTGER4 (0.70) | PTGER4PTGER2MAPK14CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11872226-B2 | N-benzyl-2-phenoxybenzamide derivatives as prostaglandin E2 (PGE2) receptors modulators | MEDIBIOFARMA, S.L. (ES) | 2024-01-16 | — | — | US | claimed |
| US-20220117962-A1 | NEW N-BENZYL-2-PHENOXYBENZAMIDE DERIVATIVES AS PROSTAGLANDIN E2 (PGE2) RECEPTORS MODULATORS | MEDIBIOFARMA, S.L. (ES) | 2022-04-21 | — | — | US | claimed |
| CN-113646299-A | Novel N-benzyl-2-phenoxybenzamide derivatives as prostaglandin E2(PGE2) receptor modulators | 梅迪比奥法尔玛公司 | 2021-11-12 | — | — | CN | claimed |
| EP-3693359-A1 | NEW N-BENZYL-2-PHENOXYBENZAMIDE DERIVATIVES AS PROSTAGLANDIN E2 (PGE2) RECEPTORS MODULATORS | MEDIBIOFARMA, S.L. (ES) | 2020-08-12 | — | — | EP | claimed |
| US-11872226-B2 | N-benzyl-2-phenoxybenzamide derivatives as prostaglandin E2 (PGE2) receptors modulators | MEDIBIOFARMA, S.L. (ES) | 2024-01-16 | — | — | US | disclosed |
| US-20220117962-A1 | NEW N-BENZYL-2-PHENOXYBENZAMIDE DERIVATIVES AS PROSTAGLANDIN E2 (PGE2) RECEPTORS MODULATORS | MEDIBIOFARMA, S.L. (ES) | 2022-04-21 | — | — | US | disclosed |
| CN-113646299-A | Novel N-benzyl-2-phenoxybenzamide derivatives as prostaglandin E2(PGE2) receptor modulators | 梅迪比奥法尔玛公司 | 2021-11-12 | — | — | CN | disclosed |
| EP-3693359-A1 | NEW N-BENZYL-2-PHENOXYBENZAMIDE DERIVATIVES AS PROSTAGLANDIN E2 (PGE2) RECEPTORS MODULATORS | MEDIBIOFARMA, S.L. (ES) | 2020-08-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220117962-A1 | NEW N-BENZYL-2-PHENOXYBENZAMIDE DERIVATIVES AS PROSTAGLANDIN E2 (PGE2) RECEPTORS MODULATORS | PTGER2, PTGER4, PTGER1 | PTGER4 2/4885PTGER2 1/4885MAPK14 904/4885 |
| US-11872226-B2 | N-benzyl-2-phenoxybenzamide derivatives as prostaglandin E2 (PGE2) receptors modulators | PTGER2, PTGER4, PTGER1 | PTGER4 2/4885PTGER2 1/4885MAPK14 890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.